Wave Life Sciences Dirección
Dirección controles de criterios 4/4
Wave Life Sciences' El consejero delegado es Paul B. Bolno , nombrado en Dec 2013, tiene un mandato de 10.17 años. la remuneración anual total es $2.67M , compuesta por 23.2% salario y 76.8% primas, incluidas acciones y opciones de la empresa. posee directamente 0.33% de las acciones de la empresa, por valor de $1.67M . La antigüedad media del equipo directivo y del consejo de administración es de 3.5 años y 7.3 años respectivamente.
Información clave
Paul B. Bolno
Chief Executive Officer (CEO)
US$2.7m
Compensación total
| Porcentaje del salario del CEO | 23.2% |
| Permanencia del CEO | 10.3yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 7.4yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09
Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Sep 24What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates
Aug 07Wave Life Sciences posts proof-of-concept data from genetic disorder study
Jun 02Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates
May 15Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade
Apr 02Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years
Feb 19Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Jan 13
Here's What We Think About Wave Life Sciences' (NASDAQ:WVE) CEO Pay
Dec 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$58m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$131m |
| Mar 31 2023 | n/a | n/a | -US$151m |
| Dec 31 2022 | US$3m | US$618k | -US$162m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$118m |
| Dec 31 2021 | US$4m | US$597k | -US$122m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$1m | US$579k | -US$150m |
| Sep 30 2020 | n/a | n/a | -US$178m |
| Jun 30 2020 | n/a | n/a | -US$196m |
| Mar 31 2020 | n/a | n/a | -US$197m |
| Dec 31 2019 | US$4m | US$579k | -US$194m |
| Sep 30 2019 | n/a | n/a | -US$175m |
| Jun 30 2019 | n/a | n/a | -US$162m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$6m | US$541k | -US$147m |
| Sep 30 2018 | n/a | n/a | -US$140m |
| Jun 30 2018 | n/a | n/a | -US$127m |
| Mar 31 2018 | n/a | n/a | -US$116m |
| Dec 31 2017 | US$3m | US$515k | -US$102m |
Compensación vs. Mercado: La compensación total de Paul B. ($USD2.67M) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD2.19M).
Compensación vs. Ingresos: Paul B.ha sido coherente con los resultados de la empresa en el último año.
CEO
Paul B. Bolno (49 yo)
10.3yrs
Permanencia
US$2,667,997
Compensación
Dr. Paul B. Bolno, M.D., MBA serves as an Independent Director at SQZ Biotechnologies Company since June 2020. Since May 2020 he has served as Chairman of the Scientific Advisory Group for the Nucleic Acid...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 10.3yrs | US$2.67m | 0.33% $ 2.0m | |
| CFO & Principal Accounting Officer | 3.3yrs | US$1.15m | 0.028% $ 165.2k | |
| Chief Technology Officer | 3.9yrs | US$1.23m | 0.079% $ 469.2k | |
| Head of Investor Relations | 5yrs | sin datos | sin datos | |
| Senior VP & General Counsel | 7.9yrs | sin datos | sin datos | |
| Senior VP of Corporate Development & Head of Emerging Areas | 7.3yrs | US$1.68m | 0.065% $ 388.2k | |
| Senior VP & Head of Human Resources | 1.3yrs | sin datos | sin datos | |
| Senior Vice President of Chemistry | 2.4yrs | sin datos | sin datos | |
| Chief Development Officer | 1.5yrs | sin datos | sin datos | |
| Senior Vice President of Translational Medicine | 1.3yrs | sin datos | sin datos |
3.6yrs
Permanencia media
50.5yo
Promedio de edad
Equipo directivo experimentado: WVEEl equipo directivo de la empresa se considera experimentado (3.3 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 10yrs | US$2.67m | 0.33% $ 2.0m | |
| Director | 10.8yrs | US$628.06k | 0.025% $ 146.1k | |
| Independent Director | 4.6yrs | US$116.65k | 0.059% $ 351.5k | |
| Independent Chairperson | 7.4yrs | US$144.15k | 0.072% $ 427.3k | |
| Independent Director | 7.2yrs | US$110.65k | 0.072% $ 427.3k | |
| Independent Director | 9.3yrs | US$92.65k | sin datos | |
| Independent Director | 11.8yrs | US$92.65k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$107.65k | 0.059% $ 351.5k | |
| Independent Director | 3.7yrs | US$94.15k | 0.047% $ 277.3k |
7.4yrs
Permanencia media
55yo
Promedio de edad
Junta con experiencia: La junta directiva de WVE se considera experimentada (7.1 años de antigüedad promedio).